Tiziana Life Sciences Ltd (TLSA) Stock Analysis & Investment Frameworks

Tiziana Life Sciences Ltd (TLSA) stock analysis on Invetso. Review Tiziana Life Sciences Ltd’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Tiziana Life Sciences Ltd Company Overview

Tiziana Life Sciences Ltd Key Financial Metrics

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

Tiziana Life Sciences Ltd Investment Frameworks

Invetso analyzes Tiziana Life Sciences Ltd (TLSA) across the following frameworks:

Explore More TLSA Research